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Supplemental Tables 
Table S1a. Characteristics of the 23 studies included in current analysis 
First author Bang 20101 Brazilian NTP2 Cattamanchi 
20093 
Chien 
20154 
Cox 20065 Gegia 20126 Huyen 20137 Jacobson 20118 
Country Denmark Brazil US (California) Taiwan Uzbekistan Georgia Vietnam South Africa 
Years of study 2002-07 2012-14 1992-2005 2004-12 2001-02 2007-09 2005-07 2001-09 
Concentration used to define H 
resistance (m/mL) 
0·1 0·2 0·2 0·2 0·1 0·2 0·2 0·1 
Regimena Indiv. Stand. Stand. Indiv. Stand. Stand. Stand. Indiv. 
Duration (known vs planned) Known Known Known Known Known Planned Planned Known 
Age in years (median, IQR) 37 
(27; 47) 
41 
(31; 52) 
48 
(30; 67) 
63 
(48; 76) 
31 
(25; 40) 
35 
(26; 48) 
49  
(39; 65) 
40  
(31; 46) 
Sex female, % 35% 30% 38% 25% 30% 23% 25% 44% 
HIV positive, % of testedb 27% 6% 7% 2% 0% na na 27% 
Past TB treatment, %b 13% na 36% 12% 53% 14% 16% 80% 
Cavity on chest-x ray, %b na 69% 21% 28% na na na na 
Resistance to SM, %b 50% 4% na na 78% 69% 65% 0% 
Total analyzable, N:  
- Success, % 
- Failure/relapse, % 
- Deaths, % 
- Loss to follow-up, % 
71 
83% 
4% 
3% 
10% 
167 
67% 
15% 
4% 
14% 
98 
90% 
1% 
1% 
8% 
242 
86% 
4% 
10% 
0 
55 
31% 
49% 
5% 
15% 
864 
70% 
9% 
4% 
17% 
204 
85% 
9% 
5% 
1% 
23 
65% 
22% 
0 
13% 
N included in analysis:  
- Mortality 
- Success 
- Acquired R resistance 
 
64 
61 
-- 
 
144 
107 
-- 
 
90 
55 
-- 
 
242 
133 
127 
 
47 
23 
11 
 
716 
686 
649 
 
201 
32 
-- 
 
20 
6 
6 
Notes:   a) Regimens were classified as “standardized” if standard regimen was given to all patients; “individualized” if regimens were tailored to individual 
patients’ characteristics such as prior therapy, or drug susceptibility testing (DST) results; “ randomized” if standard regimens were given within a randomized 
clinical trial. 
b) Percentages are of the total for who the information was available. In some sites this information was available for less than 50% of the population 
Abbreviations: H isoniazid; Individ. Individualized; IQR Interquartile range; na: information in not available for that database or if it is available in less than 
10% of the population; R: rifampin;  Random. Randomized;  SM streptomycin; Stand. Standardized.  
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Table S1a -continued. Characteristics of the 23 studies included in current analysis 
First author Jones-
Lopez 20119 
Kim 200810 Lee 201611 Munang 
201512 
Netherlands NTP13 New York 
city14 
Ohkado 
200615 
Park 201616 
Country Uganda Korea Korea UK Netherlands US Philippines Korea 
Years 2005 2001-05 2005-12 1999-2010 1993-2015 1994-2014 2000 2005-13 
Concentration used to define H 
resistance (m/mL) 
 
0·1 
 
0·2 
 
0·2 
 
0·1 
 
0·2 
 
0·1; 0·2 
 
0·2 
 
0·2 
Regimena Stand. Stand. Stand. Indiv. Indiv. Indiv. Stand. Indiv. 
Duration (known vs planned) Planned Planned Known Known Known Known Known Known 
Age in years (median, IQR) na 43  
(31; 61) 
54  
(38; 67) 
30 
(25; 38) 
30  
(23; 40) 
41 
(30; 54) 
43  
(26; 57) 
59 
(49; 73) 
Sex female, % na 33% 34% 50% 42% 36% 30% 31% 
HIV positive, % on testedb 44% 0% 0% 5% na 24% na 0% 
Past TB treatment, %b 100% 36% 30% na 7% 3% 3% 50% 
Cavity on chest-x ray, %b na 41% 24% 15% na 25% na 31% 
Resistance to SM, %b na 13% 14% na na 36% 40% 13% 
Total analyzable, N:  
- Success, % 
- Failure/relapse, % 
- Deaths, % 
- Loss to follow-up, % 
34 
68% 
9% 
18% 
6% 
39 
92% 
8% 
0 
0 
115 
90% 
10% 
0 
0 
41 
83% 
5% 
0 
12% 
509 
87% 
0 
2% 
11% 
824 
88% 
1% 
6% 
5% 
33 
82% 
6% 
3% 
9% 
6 
100% 
0 
0 
0 
N included in analysis:  
- Mortality 
- Success 
- Acquired R resistance 
 
32 
26 
26 
 
39 
13 
12 
 
115 
91 
83 
 
36 
12 
12 
 
454 
15 
-- 
 
778 
541 
539 
 
30 
2 
-- 
 
6 
5 
-- 
Notes: 
a) Regimens were classified as “standardized” if standard regimen was given to all patients; “individualized” if regimens were tailored to individual patients’ 
characteristics such as prior therapy, or drug susceptibility testing (DST) results; “ randomized” if standard regimens were given within a randomized clinical 
trial. 
Abbreviations: H isoniazid; Individ. Individualized; IQR Interquartile range; na: information in not available for that database or if it is available in less than 
10% of the population; R: rifampin; SM streptomycin; Stand. Standardized.  
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Table S1a-continued. Characteristics of the 23 studies included in current analysis  
First author Quy 
2003,200617,18 
Reves 201419 Romanowski 
201720 
Skrahina21 Swaminathan 
201022  
Viiklepp23 Yoshiyama 
201024 
Total 
Country Vietnam US & Canada Canada Belarus India Estonia Nepal --  
Years 1998-2000 1999-2004 2002-14 2012-15 2000-05 2008-15 2003-05 1992-2015 
Concentration used to define H 
resistance (m/mL) 
 
0·2 
 
0·2 or 1·0  
 
0·1 
 
0·1 
 
1·0 
 
0·1 
 
0·25 
 
-- 
Regimen a Stand. Stand. Indiv. Indiv. Random.  Indiv. Stand. -- 
Duration (known vs planned) Planned Known Known Known Planned Known Planned -- 
Age in years (median, IQR) 38 
(30; 46) 
45 
(33; 56) 
49 
(37; 65) 
43 
(33; 53) 
35 
(29; 37) 
49 
(39; 56) 
30 
(25; 41) 
35 
(25; 50) 
Sex female, %  30% 30% 32% 39% 26% 22% 41% 31% 
HIV positive, % of testedb 2% 0% 3% 0% 100% 12% na 13% 
Past TB treatment, %b 27% 17% 18% 12% na 7% 100% 16% 
Cavity on chest-x ray, %b na 45% 42% 0% 9% 54% na 32% 
Resistance to SM, %b 72% 25% 28% 67%b 43% 74% 65% 47% 
Total analyzable, N:  
- Success, % 
- Failure/relapse, % 
- Deaths, % 
- Loss to follow-up, % 
315 
81% 
9% 
3% 
7% 
60 
75% 
3% 
0 
22% 
121 
80% 
1% 
4% 
15% 
15 
60% 
20% 
0 
20% 
25 
36% 
48% 
8% 
8% 
42 
79% 
2% 
14% 
5% 
20 
75% 
10% 
0 
15% 
3923 
80% 
6% 
4% 
10% 
N included in analysis:  
- Mortality  
- Success 
- Acquired R resistance 
 
294 
101 
-- 
 
47 
45 
-- 
 
103 
44 
44 
 
12 
11 
10 
 
23 
4 
3 
 
40 
14 
14 
 
17 
17 
16 
 
3,550 
2,044 
1,552 
Notes: 
a) Regimens were classified as “standardized” if standard regimen was given to all patients; “individualized” if regimens were tailored to individual patients’ 
characteristics such as prior therapy, or drug susceptibility testing (DST) results; “ randomized” if standard regimens were given within a randomized clinical 
trial. 
Abbreviations: H isoniazid; Individ. Individualized; IQR Interquartile range; na: information in not available for that database or if it is available in less than 
10% of the population; R: rifampin; SM streptomycin; Stand. Standardized.  
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Table S1b. Regimens excluded from present analysis –in the 23 included studies. Note: regimens were 
excluded if they did not correspond to the three study questions. 
 
Regimen N data sets N  
Regimens excluded from present analysis   817 
Any regimens with high-dose isoniazid 
- High dose H plus R, E, Z 
- High dose H plus R, E, Z, SM 
- Containing both FQ and high dose H (+/- SM) 
- Containing high does H, group C or D3 drugsa +/- FQ +/- any injectables 
- Other combinations with high dose H 
 139 
63 
22 
31 
17 
6 
Containing WHO Group C or D3 drugs (+/-SM, +/- FQ) (without high dose H) 
- Ethionamide/prothionamide 
- Cycloserine/terizidone 
- Both Ethionamide/prothionamide and Cycloserine/terizidone 
- Other group C or D3 drugsb 
 141 
69 
36 
19 
17 
(H)REZ-Second line injectables  (+/- SM)  19 
(H)REZ- FQ- Second line injectables (+/- SM)  73 
Other regimens containing FQ 
- (H)RE + FQ (+/- SM) 
- (H)RZ + FQ (+/-SM) 
- (H)REZ-SM-FQ 
- Other combinations  
 240 
74 
65 
56 
45 
Other regimens (RZ, RE, EZ) without FQ or injectables 
- H, 6R 2Z, SM  
- H, 6RZ 
- H, 9RE 
- Others 
 205 
108 
39 
37 
21 
Notes:  
a) Group C or D3 drugs used were Ethionamide/prothionamide or Cycloserine/terizidone or p-amynosalicidic 
acid (PAS) 
b) Group C or D3 drugs used were Clofazimine, Linezolid,  p-amynosalicidic acid (PAS), Macrolides, 
Thioacetazone 
Abbreviations: E: Ethambutol; FQ: fluoroquinolones; (H)= isoniazid used in some, but not all regimens. R : 
rifampin (when patients used rifabutin in place of rifampin is specified in the notes); SM: Streptomycin;  Z= 
pyrazinamide 
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Table 1Sc: Dosages of drugs used at sites of studies included in the individual patient data meta-analysis on isoniazid-resistant TB.  
Author 
Drug 
First line drugs Fluoroquinolones Injectable 
H R E Z Ofloxacin Levofloxacin Moxifloxacin Ciprofloxacin SM 
Bang1 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
600 mg/day not used 400 mg/day 500 mg twice a 
day 
12-18 
mg/kg/day 
Brazilian NTB2 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
400mg/kg According to 
weighta  
400 mg/day Note used Accoding to 
weightb 
Cattamanchi3 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used 750-1000 
mg/day 
400 mg/day not used not used 
Chien4 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used 750-1000 
mg/day 
400 mg/day not used not used 
Cox5 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used not used not used not used 12-18 
mg/kg/day 
Gegia6 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used 750-1000 
mg/day 
400 mg/day not used not used 
Huyen7 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used not used not used not used 12-18 
mg/kg/day 
Jacobson8 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used not used not used not used 12-18 
mg/kg/day 
Jones-Lopez9 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used not used not used not used 12-18 
mg/kg/day 
Notes:  
a) According to weight: 20 kg: 10/mg/kg/day ; 21-35 kg: 250 mg-500 mg/day; 35-50 kg:500-750 mg/day;>50 kg: 750 mg/day. 
b) 20 kg: 20 mg/kg/day; 21-35 kg: 500 mg/day ; 36-50 kg: 750-1000 mg /day; >50 kg:1000 mg /day 
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Table 1Sc (continued): Dosages of drugs used at sites of studies included in the individual patient data meta-analysis on isoniazid-resistant TB.  
Author Drug 
first line drugs Fluoroquinolones Injectable 
H R E Z Ofloxacin Levofloxacin Moxifloxacin Ciprofloxacin SM 
Kim10 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
400mg bid 750-1000 
mg/day 
400 mg/day not used 12-18 
mg/kg/day 
Lee11 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used 750-1000 
mg/day 
400 mg/day not used 12-18 
mg/kg/day 
Munang12 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used not used 400 mg/day 500 -750 mg bid 12-18 
mg/kg/day 
Netherlands 
NTB13 
4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used not used 400 mg/day not used not used 
NYC TB14 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
800 mg/day 500-1000 
mg/day 
400 mg/day 1000-1500 
mg/day 
12-18 
mg/kg/day 
Ohkado15 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used not used not used not used 12-18 
mg/kg/day 
Park16  4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used 750-1000 
mg/day 
400 mg/day not used 12-18 
mg/kg/day 
Quy17,18 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used not used not used not used 12-18 
mg/kg/day 
Reves19 not used  600 mg, daily 
for at least 2 
weeks then 
mostly bi-
weekly, some 
thrice weekly 
daily for at least 
2 weeks then 
biweekly EMB 
40–50 mg/kg 
and  
25–35 mg/kg 
thrice weekly  
daily for at least 
2 weeks then 
biweekly PZA 
40–70 mg/kg 
and 30–40 
mg/kg thrice 
weekly 
not used not used not used not used not used 
Romanowski20 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used 750-1000 
mg/day 
not used not used 12-18 
mg/kg/day 
Skrahina21 4-6 mg/kg/day 8-12 mg/kg/day max 1600 
mg/kg/day 
30-30 
mg/kg/day 
800 mg/day 750-1000 
mg/day 
400 mg/day not used not used 
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Table 1Sc (continued): Dosages of drugs used at sites of studies included in the individual patient data meta-analysis on isoniazid-resistant TB.  
Author Drug 
First line drugs Fluoroquinolones Injectable 
H R E Z Ofloxacin Levofloxacin Moxifloxacin Ciprofloxacin SM 
Swaminathan22  10 mg/Kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
not used not used not used not used not used 
Viiklepp23 4-6 mg/kg/day 8-12 mg/kg/day 5-25 mg/kg/day 20-30 
mg/kg/day 
not used 750-1000 
mg/day 
400 mg/day not used 12-18 mg/kg 
Yoshiyama24 4-6 mg/kg/day 8-12 mg/kg/day 15-25 
mg/kg/day 
20-30 
mg/kg/day 
 not used  not used  not used  not used 12-18 mg/kg 
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Table 1Sd: Summary of treatment outcome definitions used in studies included in individual patient data meta-analysis. 
Study 
Outcome definition 
Cure Treatment Completed Lost to follow-up Treatment Failure Treatment Relapse 
WHO  
(Reference Standard) 
A patient whose sputum smear 
or culture was positive at the 
beginning 
of the treatment but who was 
smear- or culture-negative in 
the last 
month of treatment and on at 
least one previous occasion. 
A patient who completed 
treatment but who does not 
have a negative 
sputum smear or culture result 
in the last month of treatment 
and on at 
least one previous occasion 
A patient whose treatment was 
interrupted for 2 consecutive 
months or 
more. 
A patient whose sputum smear 
or culture is positive at 5 
months or later 
during treatment. Also 
included in this definition are 
patients found to 
harbour a multidrug-resistant 
(MDR) strain at any point of 
time during 
the treatment, whether they 
are smear-negative or -
positive. 
Recurrence of 
bacteriologically confirmed 
tuberculosis after treatment 
success (cure or treatment 
complete). 
Bang1 Same Same Same Patient who is sputum smear 
positive or culture positive at 
five months or later during 
treatment 
Same 
Brazilian NTB2 Same Same Treatment interruption for 30 
days or more 
Same Same 
Cattamanchi3 Same Same  Same Same 
Note: “Same” means : as WHO reference definition.
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Table 1Sd (continued): Summary of treatment outcome definitions used in studies included in individual patient data meta-analysis. 
Study 
Outcome definition 
Cure Treatment Completed Lost to follow-up Treatment Failure Treatment Relapse 
Chien4 Same Same Same Same Same 
Cox5 Same Same Same Same Same 
Gegia6 Same Same Same Same Same 
Huyen7 Same Same Same Any positive sputum or 
culture at 5 months or later 
during treatment 
Recurrent TB with initial and 
follow-up M. tuberculosis 
isolates had identical 
spoligotypes and VNTR 
patterns, or if the VNTR 
patterns differed by "1 locus, 
and as reinfection if 
otherwise" 
Jacobson8 Same Same Same Same Not measured 
Jones-Lopez9 Treatment completed and one 
negative culture on solid 
medium at the end of 
treatment 
Completed 8 months of 
treatment and free of Tb 
symptoms at the first post-
treatment follow-up visit 
 Patients culture positive at 
month 8 OR patients with no 
culture positive at month 5 
and with no culture at month 8 
and no confirmation that they 
were free of TB after the end 
of treatment  
  
Note: “Same” means same as WHO reference definition. 
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Table 1Sd (continued): Summary of treatment outcome definitions used in studies included in individual patient data meta-analysis. 
Study 
Outcome definition 
Cure Treatment Completed Lost to follow-up Treatment Failure Treatment Relapse 
Kim10 Same Same Same Same Same 
Lee 11 Same Same Same Same Same 
Munang12 Combined with complete (see) Patients were considered 
successfully treated if they 
completed a full course of 
prescribed treatment and had 
documented sputum culture 
conversion (for sputum 
culture-positive cases) or were 
discharged by their attending 
physician. 
Same Treatment failed if a case was 
smear- or culture- positive at 
month 5 or later during 
treatment. 
Suspected OR 
bacteriologically confirmed 
tuberculosis after treatment 
success (cure or complete). 
Netherlands NTB 13 Negative sputum culture result 
after initial positive culture 
test.  
Same Same Same Not collected  
NYC TB14 Same Same  Lost to follow-up, adverse 
reaction that resulted in the 
discontinuation of treatment, 
or refusal of treatment 
Positive culture after culture 
conversion 
Treatment was restarted after 
treatment completion  
Ohkado15 A sputum smear positive 
patient who has been 
completed treatment and is 
sputum smear negative in the 
last month of treatment and on 
at least one previous occasion. 
Same Same A patient who is sputum 
smear-positive at five months 
or later during the treatment 
OR a sputum smear-negative 
patient who becomes smear-
positive during the treatment. 
Same 
Note: “Same” means : as WHO reference definition.
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Table 1Sd (continued): Summary of treatment outcome definitions used in studies included in individual patient data meta-analysis. 
Study 
Outcome definition 
Cure Treatment Completed Lost to follow-up Treatment Failure Treatment Relapse 
Park16 Same Same Same Same Same 
Quy17,18 Same Same Same Positive smear at 5 months of 
later during treatment 
Same 
Reves19 Same Same Same Treatment failure was 
suspected for a positive TB 
culture following 16 calendar 
weeks of treatment, and 
relapse was suspected for a 
positive TB culture within 2 
years of treatment completion. 
Relapse was suspected for a 
positive TB culture within 2 
years of treatment completion. 
Romanowski20 Same Same Same Same Same 
Skrahina21 Same same Same Same Same 
Swaminathan22 All cultures negative in the 
last 2 months of treatment  
Clinical resolution with 
regression of nodes or 
radiographic clearance  
Same Same Same 
Viiklepp23 Same Same Same Same Same 
Yoshiyama24 Same Same Same Same Same 
Note: “Same” means : as WHO reference definition 
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Table S1E: Assessment of Quality of the Included studies 
 
Study 
1. 
Sampling 
method 
2. Outcome measures 
3. Participation 
rate (%) 
4. Lost to follow-up 
rate (%) 
5.-8. Completeness of information (%) 
Overall Study 
Quality 
Post-treatment 
Follow-up 
>=12mo (%) 
Culture confirmed cure 5. Age 6. HIV 7. Cavity 8. AFB 
Bang1  census 100 Yes 100 9·0 100 21·6
a 6·3 100 High 
Brazilian NTP2  census 0 Yes 100 15·2 100 77·0
 b 98·4 82.7 High 
Cattamanchi3 census 62 Yes 100 9·5 100 100 97.1 100 High 
Chien4 census 21 Yes 100 7·0 99·7 92·1 100 100 High 
Cox5  census 100 No 68 14·3 100 100 0 100 Moderate 
Gegia6  census 0 No 100 18·6 100 0
 a 0 96·6 Moderate 
Huyen7  census 100 Yes 97·5 1·5 99·5 0
 a 0 100 High 
Jacobson8 census 0 Yes 100 33·8 100 83·8 0 96·0 High 
Jones-Lopez9  census 100 Yes 100 5·9 0 100 0 100 High 
Kim10  census 31 Yes 100 13·0 100 71·8
 a 100 100 High 
Lee11  census 55 Yes 100 5·9 100 100 100 100 High 
Munang12  census 7 Yes 100 10·1 100 100 100 79·8 High 
Netherland NTP13 census 0 No 100 10·9 100 9·6
 a 0 52·2 Low 
NYC14 census 0 Yes 100 6·2 100 74·6
 b 84·7 99·4 High 
Ohkado15  census 0 No 83·3 18·9 100 0
 a 0 100 Moderate 
Park16 census 100 Yes 100 0 100 100 100 100 High 
Quy17,18  census 0 No 95·8 6·7 100 100 0 100 Moderate 
Reves19  RCT 81 Yes 100 4·2 100 100 94·4 88·7 High 
Romanowski20  census 43 Yes 100 8·0 99·5 99·5 96·5 100 High 
Skrahina21 census 0 Yes 100 10·3 100 100 100 100 High 
Swaminathan22 RCT 100 Yes 57·8 7·4 100 100 100 100 High 
Viklepp23  census 0 Yes 100 7·8 100 97·4 98·3 100 High 
Yoshiyama24 census 100 Yes 100 15·0 100 0
 a 0 100 High 
 
Notes: a) HIV prevalence is reported to be less than 10% in TB cases in the Country of the study, therefore the reporting on HIV was considered of high quality.  
b) HIV prevalence is reported to be less than 1% in the general population in the Country of the study (i.e., low HIV prevalence), therefore the reporting on HIV 
was considered of high quality.  
Definitions used for quality assessment:  
Critical criteria: 
1. What is the sampling method in the study: census (all patients), random sampling, or convenience sampling? (Must be census or random) 
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2. Was end of treatment outcome "cure" confirmed with culture, or were at least 80% of patients with cure/complete outcome followed for at least 1 year 
for recurrence? (Must be yes to either). 
Important criteria 
1. Was the participation rate in the study >80% 
2. Lost to follow-up rate - defined as : LFU + transferred out (if in DOT or surveillance program, not counted if in tertiary hospital) + unknown outcome. 
LFU rate must be <=10%. 
3. Was age reported in at least 90% of the participants? 
4. Was HIV status reported in at least 80% of the participants? (If HIV prevalence is known to be less than 10% in TB cases, or less than 1% in the general 
population in the country (i.e., low HIV prevalence), this item will be considered acceptable even if HIV status for individuals is not reported) 
5. Was cavity reported in at least 80% of the participants? 
6. Was AFB reported in at least 80% of the participants? 
High quality: Both critical criteria and at least 4 of the 6 important criteria. 
Moderate quality: Both critical criteria and 3 of the 6 important criteria OR 1 critical criteria and at least 4 of the 6 important criteria. 
Low quality: all remaining.  
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Table S2a. Characteristics of 10 studies excluded from current IPD analyses. Note: studies were excluded, after the data was received, if no patients received 
any of the specific regimens of interest for the three research questions. 
First author BanuRekha  
201225  
Bonnet 
201126 
Cegielski27 Escalante 
200128 
Garcia-Prats 
201629 
Gillespie 
201430 
Glynn 
201531 
Merle 
201432  
Swaminathan 
201133 
Tabarsi 200934 Total  
Country India Georgia US (Texas) US (Texas) South Africa Multiple Malawi Multiple India Iran -- 
Years 2004-06 2003-13 1984-2007 1990-97 2006-12 2013 1986-2015 2007 2006-08 2003-15 1984- 2015 
Concentration used to 
define H resistance 
(m/mL) 
 
1·0 
 
0·1 
 
1·0 
 
0·4 
 
0·1 
 
0·1  
 
varied over 
time 
 
0·2 
 
1·0 
 
0·2 
 
-- 
Regimen a Random. Indiv. Indiv. Indiv. Indiv. Random. Stand. Random. Random. Indiv. -- 
Duration (known vs 
planned) 
Planned Known Known Known Known Planned Known Planned Planned Known -- 
Age in years (median, 
IQR) 
32 
(27; 39) 
43 
(32; 52) 
46 
(29; 60) 
39 
(25; 49) 
4 (2;7) 30 
(24; 45) 
37 
(30; 45) 
26  
(23; 36) 
35  
(32; 35) 
47 
(34; 60) 
35  
(25; 48) 
Sex female, %  27% 18% 24% 22% 58% 34% 37% 27% 40% 32% 34% 
HIV positive, % of testedb 0% na 8% 9% 22% 9% 35% 8% 100% 11% 14% 
Past TB treatment, %b 3% 42% 39% 24% 29% 0% 23% na 0% 84% 34% 
Cavity on chest-x ray, %b na 44% na 65% 23% 71% na 45% na 74% 58% 
Resistance to SM,% b na 79% 24% 37% 11%b 27% 23% 14% 0% 41%c 38% 
Analyzable population, N 30 59 43 51 51 127 201 68 5 127 762 
Notes: 
a) Regimens were classified as “standardized” is standard regimen was given to all patients; “individualized” if regimens were tailored to individual patients’ 
characteristics such as prior therapy, or drug susceptibility testing (DST) results; “ randomized” if a standard regimens were given within a randomized clinical 
trial; b) percentage are on total available information. In some sites this information was available for less than 50% of the population 
Abbreviations: DST: drug susceptibility test; H isoniazid; Individ. Individualized; IQR Interquartile range; na: information in not available for that database or 
if it is available in less than 10% of the population; Random. Randomized;  SM streptomycin; Stand. Standardized.  
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Table S2b: Regimens used in the 10 excluded studies  
Regimen N  
Total patients in the 10 studies  762 
(H) REZ 
- 6(H)R, 2E, 2Z 
- unknown duration 
261 
204 
57 
REZ(H)-FQ 
-4(H)R 2E, 2Z, FQ 
-unknown duration 
105 
46 
59 
REZ(H)-SM  30 
Other regimens  366 
Included high dose isoniazid 35 
Included Ethionamide/prothionamide or Cycloserine/Terizidone  66 
Included Thioacetazone 63 
Included Clofazimine 2 
Other combinations of H, R, E, Z (other than HREZ) 11 
Other combinations of H, R, E, Z, SM (other than HREZ-SM)  11 
Used second line injectables   6 
Used FQ and second line injectables  74 
Used Other FQ-containing regimens 87 
Used  combinations of FQ and SM 11 
Notes:  
Abbreviations: H: Isoniazid, E: Ethambutol,  FQ: fluoroquinolones; SM: Streptomycin;  R: Rifampin; Z: 
pyrazinamide.  
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Table S3: Characteristics of the populations included in analyses of success and acquired rifampin resistance for 6(H)REZ versus >6(H)REZa  
Type of analysis Analyses of Success (n=1350) 
Analyses of Acquired Rifampin resistance 
(n=1160) 
Regimens compared 6(H)REZ  >6 (H)REZ 6(H)REZ  >6 (H)REZ 
Total Nb 
 
262 1088c 168 992c 
High Income Country, N(%) 260/262(99)* 397/1088 (36)  166/168 (99)* 338/992(34)  
Age (median, IQR) 42 (29; 58)* 37 (27; 50) 43 (30; 61)* 36 (27; 50) 
Sex, female, N /tot with info (%) 84/262 (32) 317/1088 (29) 53/168 (32) 286/992 (29) 
HIV: positive, N/tot with info (%) 7/221 (3)* 23/295 (8) 5/142 (4) 20/257 (8) 
on Antiretroviral therapy, N (% on HIV+)  1/7 (14) 1/23 (4) 0/5 (0) 1/20 (5) 
Diabetes, N/tot with info (%) 16/113 (14) 19/99 (19) 5/66 (8) 14/86 (16) 
Any Past TB treatment, N/tot with info (%) 44/260 (17)* 116/979 (12) 17/166 (10) 91/888 (11) 
Sputum smear positive, N/tot with info (%) 127/252 (50)* 853/1071 (80) 81/166 (49)* 780/976 (80) 
Cavity on chest X-ray, N/tot with info (%) 54/237 (23)* 115/366 (31) 27/164 (16)* 103/329 (31) 
Poly resistance (resistance to E, Z or SM if used), N/tot 
with info, % 
2/262(1) 3/1088(0) 2/168 (1) 3/992 (0) 
Resistance to SM, N/total tested  63/209 (30)* 598/1053 (57) 51/165 (31)* 559/986 (57) 
Resistance to E, N/total tested  1/261(0) 3/1086 (0) 1/167 (1) 3/990 (0) 
Resistance to Z, N/total tested 1/224 (0.5) 0/325 (0) 1/138 (1) 0/273 (0) 
On DOT, N/tot with info(%) 81/162 (50)* 760/842(90) 25/68 (37)* 707/747(95) 
Duration in months, median (IQR): 
- Rifampin 
- Pyrazinamide 
 
6·1 (6·0; 6·5) 
6·1 (6·0; 6·4) 
 
9·0 (9·0; 9·0) 
9·0 (9·0; 9·0) 
 
6·1 (6·0; 6·5) 
6·1 (6·0; 6·5) 
 
9·0 (9·0; 9·0) 
9·0 (9·0; 9·0) 
Notes: * p<0. ·05 for Chi Squared tests (or Fisher’s exact test) for categorical variables, and from T Tests for continuous variables ;  
a) Treatment was administered daily for all but 1 study (n=45 subjects) included in this analysis  
b) A total of 13 children under 14 years old were treated in population analyzed for success and 9 in analyzed for acquired rifampin resistance;  
c) Two patients took rifabutin and rifampin. 
Abbreviations: DOT: directly observed therapy; IQR: Inter Quartile Range;  E: Ethambutol; (H)= Isoniazid used in some, but not all regimens SM: Streptomycin;  
R: Rifampin; Z: pyrazinamide.  
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Table S4: Characteristics of the population included in analyses of FQ added to >6(H)REZ. 
Type of analysis 
Analyses of Mortalityh 
(n=2698) 
Analyses of Success 
(n=1601) 
Analyses of Acquired Rifampin 
resistance 
(n=1381) 
Regimens compared ≥6(H)REZ  FQ ≥6 (H)REZ ≥6(H)REZ  FQ ≥6 (H)REZ ≥6(H)REZ  FQ ≥6 (H)REZ 
Total N 524a 2174b 251c 1350d 221c 1160d 
High Income Country, N(%) 513 (98)* 1449 (67) 241 (96)* 657 (49) 212 (96)* 504 (43) 
Age (median, IQR)e 48 (34; 63)* 37 (27; 52) 42 (32; 56)* 38 (27; 52) 43 (33; 58)* 37 (27; 51) 
Sex, female, N /tot with info (%) 179 (34%) 711 (33%) 82 (33) 401 (30) 72 (33%)  339 (29%) 
HIV: positive, N/tot with info (%) 62/428 (14) 106/884 (12) 17/203 (8) 30/516 (6) 14/191 (7%) 25/399 (6%) 
on ART, N (% on HIV+)  6/62 (10) 3/106 (3) 0/17 (0) 2/30 (7) 0/14 (0%) 1/25 (4%) 
Diabetes, N/tot with info (%) 27/185 (15) 67/385 (17) 8/82 (10) 35/212 (17) 8/80 (10%) 19/152 (13%) 
Any Past TB treatment, N/tot with info (%) 57/508 (11) 237/1978 (12) 27/247 (11) 160/1239 (13) 21/217 (10%) 108/1054 (10%) 
Sputum smear positive, N/tot with info (%) 286/482 (59) 1412/1997 (71) 154/245 (63)* 980/1323 (74)* 134/215 (62)* 861/1141 (75) 
Cavity on chest X-ray, N/tot with info (%) 113/471 (24) 260/959(27) 56/220 (25) 169/603 (28) 54/215 (25%) 130/493 (26%) 
Poly resistance (resistance to E, Z or SM if used), N/tot 
with info, % 
38/524 (7) 26/2174 (1) 7/251 (3)* 5/1350 (0.4)* 5/221(2%)* 5/1160 (0%) 
Resistance to SM, N/total tested (%) 166/482 (34) 754/1607 (47) 82/236 (35%)* 661/1262 (53%) 70/213 (33%)* 610/1151 (53%) 
Resistance to FQ, N/total tested (%) 4/313 (1) 7/497 (1) 3/163 (2%) 3/346 (1%) 1/136 (1%) 3/306 (1%) 
on DOT, N/total tested,% 84/246 (34)* 956/1689(57) 31/114 (27)* 841/1004(84) 28/85 (33)* 732/815(90) 
Duration in months, median (IQR): 
- Rifampin 
- Fluoroquinolones 
- Pyrazinamide 
 
9·0 (6·2; 11·0) 
6·6 (3·9; 9·0)f 
7·4 (4·1; 9·5) 
 
9·0 (6·0; 9·0) 
-- 
8·0 (2·1; 9·0) 
 
9·0 (7·2; 11·2) 
6·1 (3·5; 8·4)g 
8·9 (6·8; 10·7) 
 
9·0(8·3; 9·0) 
-- 
9·0 (8·1; 9·0) 
 
9·0 (7·7; 11·1) 
5·7 (3·3; 8·1) 
9·0 (7·0; 10·6) 
 
9·0 (9·0; 9·0) 
-- 
9·0 (8·9; 9·0) 
Notes: * p<0·05 for Chi Squared tests (or Fisher’s exact test) for categorical variables, and from T Tests for continuous variables;  
a) 19 patients took rifabutin and 26 patients took both rifampin and rifabutin  b) 13 patients took rifabutin and 17 patients took both rifampin and rifabutin 
c) Four patients took both rifampin and rifabutin  d) Two patients took both rifampin and rifabutin 
e) A total of 46 children under 14 years old were included in population analyzed for mortality; 16 in analyzed for success and 11 in analyzed for acquired rifampin 
resistance;  
f) Duration may have been truncated by mortality.  
g) Duration of FQ: 104 took FQ for 1-5 months, 137 took FQ for ≥6m; 10 took FQ ≥1m (unknown duration, but at least one month).   
Abbreviations: DOT: directly observed therapy; IQR: Inter Quartile Range;  E: Ethambutol;  FQ: fluoroquinolones; (H)= Isoniazid used in some, but not all 
regimens ; SM: Streptomycin; R: Rifampin; Z: pyrazinamide.  
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Table S5: Characteristics of the population included in analyses of “FQ with short Z” question (i.e. Six months or more of RE plus 1-3 months of Z plus 
fluoroquinolone compared to 6 months or more of REZ - with or without isoniazid) 
Type of analysis Analyses of Success 
(n=1468) 
Analyses of Acquired rifampin resistance 
(n=1273) 
Regimens compared ≥6(H)RE  1-3Z FQ ≥6 (H)REZ ≥(H)6RE  1-3Z FQ ≥6 (H)REZ 
Total N 118a 1350b 113a 1160b 
Agec (median, IQR) 56 (38; 69)* 38 (27; 52) 56 (38; 68)* 37 (27; 51) 
High income countries (N,%) 118 (100)* 657 (49) 113 (100)* 504 (43) 
Sex, female, N /tot with info (%) 39/118 (33) 401/1350 (30) 36 (32%) 339 (29%) 
HIV: positive, N/tot with info (%) 7/97 (7) 30/516 (6) 7/92 (8%) 26/399 (6%) 
On antiretroviral treatment, N (% on HIV+)  3/7 (43)* 2/30 (7) 3/7 (43%)* 1/25 (4%) 
Diabetes, N/tot with info (%) 10/51 (20) 35/212 (17) 8/48 (17%) 19/152 (13%) 
Any Past TB treatment, N/tot with info (%) 12/109 (11) 160/1239 (13) 10/104 (10%) 108/1054 (10%) 
Sputum smear positive, N/tot with info (%) 47/96 (49)* 980/1323 (74) 47/91 (52%)* 861/1141 (75%) 
Cavity on chest X-ray, N/tot with info (%) 28/115 (24) 169/603 (28) 27/110 (25%) 130/493 (26%) 
Poly resistance (resistance to E, Z or SM if used), N/tot 
with info, % 
15/118 (13)* 5/1350 (0.4) 15/113 (13%)* 5/1160 (0%) 
Resistance to SM, N/total tested  37/113 (33%)* 661/1262 (52%) 37/110 (34%)* 610/1151 (53%) 
Resistance to FQ, N/total tested 1/66(2%) 3/346 (1%) 1/64 (2%) 3/306 (1%) 
on DOT, N/total tested,% 23/60 (38)* 841/1004(84) 21/55 (38%)* 732/815 (90%) 
Duration in months, median (IQR): 
- Rifampin 
- Fluoroquinolones 
- Pyrazinamide 
 
9·6 (8·6; 11·9) 
7·0 (5·0; 9·5)d 
2·5 (1·9; 3·8) 
 
9·0 (8·3; 9·0) 
-- 
9·0 (8·1; 9·0) 
 
9·5 (8·6; 11·8) 
7·0 (5·0; 9·5) 
2·5 (1·9; 3·8) 
 
9·0 (9·0; 9·0) 
-- 
9·0 (8·9; 9·0) 
Notes:  
a) Three patients took both rifampin and rifabutin 
b) Two patients took both rifampin and rifabutin 
c) A total of 13 children under 14 years old were included in population analyzed for success; and 9 in population analyzed for acquired rifampin resistance.  
d) Duration of FQ: 31 had 1-5m of FQ; 71 ≥6m and 16 ≥1m (unknown duration, but at least one month).  
Abbreviations: DOT: directly observed therapy; IQR: Inter Quartile Range;  E : ethambutol;  FQ: fluoroquinolones; (H)= isoniazid used in some, but not all 
regimen;  SM: Str ptomycin;  R:rifamp n  Z: pyrazin mide
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Table S6. Characteristics of the populations included in Streptomycin-related analyses.  
Type of analysis 
Analysis of Mortality 
(n=3,026) 
Analysis of Success 
 (n=1,675) 
Analysis of Acquired rifampin resistance 
(n=1,218) 
Regimens compared (H)REZ  SM (H)REZ ≥6(H)R(E) 1-3Z  1-3SM ≥6 (H)REZ 
≥6(H)R(E) 1-3Z  
1-3SM 
≥6 (H)REZ 
Total N 763 2263
a 325 1350b 58 1160b 
Agec (median, IQR) 42 (32; 52)* 37 (27; 51) 42 (31; 51) 38 (27; 52) 35 (25; 40)* 37 (27; 51) 
High Income Countries, N(%) 52/763 (7) 1449/2263 (64) 13 (4)* 657 (49) 2 (3)* 504 (43) 
Sex, female, N /tot with info (%) 197/731 (27)* 739 (33)  84/300 (28%) 401/1350 (30) 10/32 (31%) 339 (29%) 
HIV: positive, N/tot with info (%) 33/495 (7)* 131/943 (14) 17/238 (7%) 30/516 (6) 12/42 (29%)* 25/399 (6%) 
On Antiretroviral treatment, N (% on HIV+) 3/33 (9) 3/131(2) 0/17 (0%) 2/30 (7) 0/12 (0%) 1/25 (4%) 
Diabetes, N/tot with info (%) 18/166 (11) 69/413 (17) 13/112 (12%) 35/212 (17) 0/4(0%) 19/152 (13%) 
Any Past TB treatment, N/tot with info (%) 235/627 (37)* 238/2033(12) 204/214 (95%)* 160/1239 (13) 55/56 (98%)* 108/1054 (10%) 
Sputum smear positive, N/tot with info (%) 705/744 (95)* 1486/2077 (72) 289/312 (93%)* 980/1323 (74)* 56/58 (97%)* 861/1141 (75%) 
Cavity disease at chest X-ray, N/tot with info (%) 107/172 (62)* 272/994(27) 76/113 (67%)* 169/603 (28) 2/5 (40%) 130/493 (26%) 
Poly resistance (resistance to E, Z or SM if used), 
N/tot with info, % 
378/700 (54)* 36/2263(2) 131/281 (47)* 5/1350 (0.4)* 21/32 (66%)* 5/1160 (0%) 
Resistance to SM, N/total tested 375/700 (54) 799/1694 (47) 129/280 (46%) 661/1262 (53%) 20/32 (63%) 610/1151 (53%) 
Resistance to E, N/total tested 18/753 (2)* 23/2257 (1) 8/321 (2)* 4/1347 (0) 2/58 (3)* 4/1157 (0) 
on DOT, N/tot with info, % 286/346(83) 873/1037(84) 267/325(82) 841/1004(84) 58 (100%)* 732/815 (90%) 
Duration in months, median (IQR): 
- Rifampin 
- Pyrazinamide 
 
6·0 (2·0; 8·0) 
2·0 (2·0; 3·0) 
 
9·0 (6·0; 9·0) 
7·4 (2·0; 9·0) 
 
8·0 (6·0; 8·0) 
3·0 (2·0; 3·0) 
 
9·0 (8·3; 9·0) 
9·0 (8·1; 9·0) 
 
8·0 (8·0; 8·0) 
3·0 (3·0; 3·0) 
 
9·0. (9·0; 9·0) 
9·0 (8·9; 9·0) 
Notes: * p<0·05 for Chi-square test for differences of this characteristic in the two regimens;  
a) Thirteen patients took rifabutin, 17 took both rifabutin and rifampin   b) Two patients took both rifampin and rifabutin 
c) A total of 37 children under 14 years old were included in population analyzed for mortality; 13 in analyzed for success and 9 in analyzed for acquired rifampin 
resistance.  
Abbreviations: DOT: directly observed therapy; IQR: Inter Quartile Range; E : Ethambutol;  FQ: fluoroquinolones;  SM: Streptomycin;  R: Rifampin; Z: 
pyrazinamide. 
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Table S7. Results for analyses restricted to high income countries only – success, mortality and acquired rifampin resistance.  Note: this analysis is not 
possible for SM-REZ regimens, because very few patients received this regimen in high-income countries 
Outcome and comparison 
Regimens:  
 
N datasets 
included 
N of events/N on 
treatment 
N pairs useda 
from Propensity Score matched Analysisb 
aOR (95% CI) 
Risk Difference (per 1,000 treated with 
95%CI) 
6 (H)REZ vs >6(H)REZ    
Success 
6(H)REZ 12 252/260 260 0·7 (0·3; 2·2) No difference (from 30 fewer to 30 more) 
>6(H)REZ  387/397  1·0 (reference) reference  
Acquired rifampin resistance 
6(H)REZ   7 1/166 166 not estimable 
No difference (from 120 fewer to 130 
more) 
>6(H)REZ    1/338  1·0 (reference) reference 
>=6(H)REZ+FQ vs >=6(H)REZ 
Mortality 
REZ FQ 12 25/531  0·7 (0·4; 1·1) No difference (from 30 fewer to 30 more) 
REZ  67/1449 513 1·0 (reference) reference 
Success 
>=6(H)REZ FQ 12 237/241  2·3 (0·7; 7·6) 20 more (from 10 fewer to 50 more) 
>=6(H)REZ  639/657 238 1 .0 (reference) reference 
Acquired rifampin resistance 
>=6(H)REZ FQ 7 0/212 210 not estimable -- 
>=6(H)REZ  2/504  1·0 (reference) reference 
>=6(H)RE 1-3Z FQ vs >=6(H)REZ 
Success 
>=6(h)RE 1-3Z FQ 12 117/118  4·1 (0·4; 38·6) 30 more (from 30 fewer to 90 more) 
>=6(H)REZ  639/657 110 1.0 (reference) reference 
Acquired rifampin resistance 
>=6(h)RE 1-3Z FQ 7 0/113 105 not estimable -- 
>=6(H)REZ  2/504  1.0 (reference) reference 
Notes:  
a) Number of pairs used in propensity score matched analysis. 
b) Estimates based on pairs matched for age, sex, HIV, past TB treatment, sputum AFB smear (positive vs negative) and resistance to other drugs besides isoniazid, if 
used.  
Abbreviations: aOR: adjusted odds ratio; CI Confidence interval E: ethambutol; FQ: fluoroquinolones; (H)= isoniazid used in some, but not all regimens.  SM: 
streptomycin; R: rifampin; Z: pyrazinamide. 
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Table S8. Results for analyses of Streptomycin restricted to low and middle-income countries only - success, mortality and acquired rifampin resistance. 
Note: This analysis is possible only for SM-REZ based regimens, as other regimens are taken mostly in high-income countries 
 
Outcome and comparison 
Regimens:  
 
N datasets 
included 
N of events/N on 
treatment 
N pairs useda 
from Propensity Score matched Analysisb 
aOR (95% CI) 
Risk Difference (per 1,000 treated with 
95%CI) 
>=6(H) RE 1-3 Z 2SM vs >=6(H)REZ    
Mortality 
(H)REZ SM 11 34/711 703 1·8 (1·0; 3·2) 40 more ( from 20 more to 60 more) 
(H) REZ  36/814  1·0 (reference) reference 
Success 
>-6(H) RE 1-3 Z 2SM 11 258/312 161 0·7 (0·4; 1·3) 50 fewer (from 120 fewer to 30 more) 
>=6(H)REZ  614/693  1·0 (reference) reference 
Acquired rifampin resistance 
>-6(H) RE 1-3 Z 2SM 3 6/56 23 not estimable -- 
>=6(H)REZ  42/656  1·0 (reference) reference 
Notes:  
a) Number of pairs used in propensity score matched analysis. 
b) Estimates based on pairs matched for age, sex, HIV, past TB treatment, sputum AFB smear (positive vs negative) and resistance to other drugs besides isoniazid, if 
used.  
Abbreviations: aOR: adjusted odds ratio; CI Confidence interval E: ethambutol; FQ: fluoroquinolones; (H)= isoniazid used in some, but not all regimens.  SM: 
streptomycin;  R: rifampin; Z: pyrazinamide. 
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TABLE S9: Comparison of Outcomes in sub-group with cavitation status known, and with cavitation - vs all patients. (Notes: Analysis of patients who did not 
receive INH not shown because too few patients in sub-sample and the models did not converge; Analysis of acquired drug resistance not shown, because there was 
zero acquired resistance in one, or both groups in each analysis). 
Outcome and comparison 
Regimens:  
 
N datasets 
included 
N of events/N on 
treatment 
N pairs 
useda 
from Propensity Score matched Analysisb 
aOR (95% CI) 
Risk Difference (per 1,000 treated with 
95%CI) 
Duration of REZ - all patients (with or without isoniazid)    
Success (all patients) 
6(H)REZ   15 254/262 262 2·4 (1·0; 5·5) 
40 more per 1,000 
(from 0 difference to 80 more) 
>6(H)REZ    999/1088  1·0 (reference) (reference) 
Success (in subsample with CXR 
info - ALL) 
6(H)REZ   11 230/237 235 0·4 (0·1; 1·7) c 
20 fewer per 1,000 
(from 60 fewer to 10 more) 
>6(H)REZ    356/366  1·0 (reference) (reference) 
Success (in subsample with 
cavity) 
6(H)REZ   11 49/54 49 0·2 (0, 2·3) 
70 fewer per 1,000 
(from 220 fewer to 80 more) 
>6(H)REZ    111/115  1·0 (reference) (reference) 
Use of Fluoroquinolones - all patients (with or without isoniazid) 
Mortality  (all durations) 
(H)REZ   FQ 15 25/524 522 0·7 (0·4; 1·1) 
20 fewer per 1,000 
(from 50 fewer to 0 difference) 
(H)REZ   97/2174  1·0 (reference) (reference) 
Mortality  (all durations, in 
subsample with CXR info ALL) 
(H)REZ   FQ 12 24/471 470 0·6 (0·4; 1·0) c 
0 difference per 1,000 
(from 30 fewer to 30 more) 
(H)REZ   51/959  1·0 (reference) (reference) 
Mortality  (all durations, in 
subsample with cavity) 
(H)REZ   FQ 12 0/113  - - -D - - - D 
(H)REZ   10/260 108 1·0 (reference) (reference) 
Success 
≥6(H)REZ   FQ 15 245/251  248 2·8 (1·1 to 7·3) 
50 more per 1,000 
(from 0 difference to 90  more) 
≥6(H)REZ    1253/1350   1·0 (reference) (reference) 
Success (in subsample with CXR 
info) 
≥6(H)REZ   FQ 11 216/220  220 2·0 (0·6 to 6·9) c 
20 more per 1,000 
(from 10 fewer to 50  more) 
≥6(H)REZ    586/603   1·0 (reference) (reference) 
Success (in subsample with 
cavity) 
≥6(H)REZ   FQ 11 56/56  - - -D  - - -D 
≥6(H)REZ   
 
 160/169 55 1·0 (reference) (reference) 
Notes at the end of the table (next page). 
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Table S9 continuation 
Outcome and comparison 
Regimens:  
 
N datasets 
included 
N of events/N on 
treatment 
N pairs 
useda 
from Propensity Score matched Analysisb 
aOR (95% CI) 
Risk Difference (per 1,000 treated with 
95%CI) 
Use of Fluoroquinolone with 1-3 months PZA - all patients (with or without isoniazid) 
Success (all FQ) 
≥(H)6RE  1-3Z FQ 15 117/118 108 5·2 (0·6 to 46·7) 
40 more per 1,000 
(from 20 fewer to 90 more) 
≥6(H)REZ   1253/1350   1·0 (reference) (reference) 
Success (all FQ) in 
subsample with CXR info 
≥(H)6RE  1-3Z FQ 11 114/115 108 4·1 (0·4 to 38·7)c 
30 more per 1,000 
(from 40 fewer to 10 more) 
≥6(H)REZ   586/603   1·0 (reference) (reference) 
Success (all FQ) in 
subsample with cavity 
≥(H)6RE  1-3Z FQ 11 28/28  - - -D  - - -D 
≥6(H)REZ   160/169 25 1·0 (reference) (reference) 
Use of Streptomycin - all patients (with or without isoniazid) 
Mortality  (all durations) 
6(H)REZ + SM 23 40/763  756 0·9  (0·6 to 1·3) 
10 fewer per 1,000 
(from 30 fewer to 20 more) 
6(H)REZ   103/2263  1·0 (reference) (reference) 
Mortality (in subsample 
with CXR info) 
6(H)REZ + SM 13 11/172 172 1·0  (0·4 to 2·4)c 
0 difference per 1,000 
(from 50 fewer to 60 more) 
6(H)REZ   54/994  1·0 (reference) (reference) 
Mortality (in subsample 
with cavity) 
6(H)REZ + SM 13 5/107  1·3 (0·3, 6·3) 
10 more per 1,000 
(from 40 fewer to 60 more) 
6(H)REZ   12/272 106 1·0 (reference) (reference) 
Success  
≥6(H)RE 1-3Z  2SM 23 271/325  296 0·4 (0·2 to 0·7) 
120 fewer per 1,000 
(from 190 fewer to 60 fewer) 
≥6(H)REZ    1253/1350  1·0 (reference) (reference) 
Success (in subsample with 
CXR info) 
≥6(H)RE 1-3Z  2SM 13 94/113  113 0·1 (0·0 to 0·5)c 
140 fewer per 1,000 
(from 220 fewer to 70 fewer) 
≥6(H)REZ    586/603  1·0 (reference) (reference) 
Success (in subsample with 
cavity) 
≥6(H)RE 1-3Z  2SM 13 63/76  76 0·3 (0·1 to 0·9) 
120 fewer per 1,000 
(from 230 fewer to 10 fewer) 
≥6(H)REZ    160/169  1·0 (reference) (reference) 
 
Notes:  
a) Number of pairs used in propensity score matched analysis. 
b) Estimates based on pairs matched for age, sex, HIV status, past TB treatment, sputum AFB smear (positive vs negative) and resistance to other drugs besides 
isoniazid, if used. Percentage of patents missing information for these variables: past TB treatment: 8%; AFB smear: 2%; HIV 8%, polyresistance, age and sex: 0%. 
HIV status was missing, but assumed to be negative in 3 studies  (n =720 patients) in settings where the prevalence of HIV co-infection rate in patients with active TB 
was <5% based on WHO surveillance data. 
c) Estimates in subsample with CXR info are based on pairs matched also for cavity, in addition to other covariates used (i.e. age, sex, HIV status, past TB treatment, 
sputum AFB smear (positive vs negative) and resistance to other drugs besides isoniazid, if used. 
d) Models did not converge, and/or zero outcomes for one group in this analysis 
Abbreviations: aOR: adjusted odds ratio;  CI Confidence interval; CXR: Chest-x ray; E: ethambutol; (H)= isoniazid used in some, but not all regimens  SM: 
streptomycin;  R: rifampin; Z: pyrazinamide; FQ: fluoroquinolone. 
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TABLE S10. Duration of use of fluoroquinolones and treatment success, or acquired rifampin resistance.  
Outcome and comparison 
Regimens:  
FQ 
Comparator 
N datasets 
included 
N of events/N on 
treatment 
N pairs usedc 
from Propensity Score matched Analysisd 
aOR (95% CI) 
 
Risk Difference (per 1,000 treated 
with 95%CI) 
Analyses in all patients   (with or without isoniazid)      
Success (All duration of FQ, REZ 
for ≥6months) 
≥6(H)REZ   FQ 15 245/251  248 2·8 (1·1 to 7·3) 
50 more per 1,000 
(from 0 difference to 90  more) 
≥6(H)REZ    1253/1350   1·0 (reference) (reference) 
Success: in subsample FQ 1-
5months 
≥6(H)REZ   1-5FQ 15 106/108  108 4·2 (0·9 to 20·9) 
70 more per 1,000 
(from 10 fewer to 150  more) 
≥6(H)REZ    1253/1350   1·0 (reference) (reference) 
Success: in subsample FQ 
≥6months 
≥6(H)REZ  ≥6FQ 15 129/133  131 2·1 (0·6 to 7·1) 
30 more per 1,000 
(from 20 fewer to 90  more) 
≥6(H)REZ    1253/1350   1·0 (reference) (reference) 
Acquired rifampin resistance 
≥6(H)REZ   FQ 10 1/221b  220 0·1 (0·0 to 1·2) 
30 fewer  per 1,000 (from 60 fewer to 0 
difference) 
≥6(H)REZ   44/1160b   1·0 (reference) (reference) 
Acquired rifampin resistance: in 
subsample FQ 1-5months 
≥6(H)REZ   1-5FQ 15 0/ 106 -- not estimable not estimable 
≥6(H)REZ    44/1160   1·0 (reference) (reference) 
Acquired rifampin resistance: in 
subsample FQ ≥6months 
≥6(H)REZ  ≥6FQ 15 1/107  107 0·2 (0·0 to 2·3) 
30 fewer per 1,000 
(from 10 fewer to 30  more) 
≥6(H)REZ    1253/1350   1·0 (reference) (reference) 
 
Notes:  
a) Of the 165 treated, 67 received isoniazid for one month or more and 98 did not receive any Isoniazid;  
b) Number treated is less than in success analysis because patients with fail/relapse but no acquired drug resistance or with non-rifampin acquired resistances were 
excluded from this analysis.  
c) Number of pairs used in propensity score matched analysis. 
d) Estimates based on pairs matched for age, sex, HIV status, past TB treatment, sputum AFB smear(positive vs negative) and resistance to other drugs besides 
ISONIAZID, if used. Percentage of patents missing information for these variables: past TB treatment: 8%; AFB smear: 8%; HIV 8%, polyresistance, age and sex: 
0%. HIV was missing, but assumed to be negative in 3 studies (n=1164 patients) in settings where the prevalence of HIV coinfection rate in patients with active TB 
was <5%, based on WHO surveillance data. 
Abbreviations: aOR: adjusted odds ratio; CI Confidence interval E: ethambutol; (H)= isoniazid used in some, but not all regimens;  SM: streptomycin;  R: rifampin; 
Z: pyrazinamide; FQ: fluoroquinolone. 
 
IPD of INHR-TB - Supplemental Tables 
Manuscript accepted for publication at the Lancet Respiratory Medicine 25 
 
 
References for Appendix tables 
 
 
 
1 Bang D, Andersen PH, Andersen ÅB, Thomsen VØ. Isoniazid-resistant tuberculosis 
in Denmark: mutations, transmission and treatment outcome. Journal of Infection 
2010; 60: 452-7. 
2 Trajman A, Lisboa Bastos M, Dockhorn Costa F, Barbosa Codenotti S, Pelissari D, 
Menzies D. Factors associated with treatment outcomes in Brazilian isoniazid-
monoresistant tuberculosis cohort.  47th World Conference on Lung Health of the 
International Union Againt Tuberculosis and Lung Diseases (The Union). 
Liverpool, UK.; 2016. 
3 Cattamanchi A, Dantes RB, Metcalfe JZ, et al. Clinical characteristics and treatment 
outcomes of patients with isoniazid-monoresistant tuberculosis. Clinical Infectious 
Diseases 2009; 48: 179-85. 
4 Chien JY, Chen YT, Wu SG, Lee JJ, Wang JY, Yu CJ. Treatment outcome of 
patients with isoniazid mono-resistant tuberculosis. Clin Microbiol Infect 2015; 21: 
59-68. 
5 Cox H, Kebede Y, Allamuratova S, et al. Tuberculosis recurrence and mortality 
after successful treatment: impact of drug resistance. PLOS Med 2006; 3: e384. 
6 Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among 
tuberculosis patients with isoniazid resistance in Georgia, 2007–2009. The 
international journal of tuberculosis and lung disease: the official journal of the 
International Union against Tuberculosis and Lung Disease 2012; 16: 812. 
7 Huyen MN, Cobelens FG, Buu TN, et al. Epidemiology of isoniazid resistance 
mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents 
Chemother 2013; 57: 3620-7. 
8 Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. 
Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape 
Province, South Africa. Clinical Infectious Diseases 2011; 53: 369-72. 
9 Jones-Lopez EC, Ayakaka I, Levin J, et al. Effectiveness of the standard WHO 
recommended retreatment regimen (category II) for tuberculosis in Kampala, 
Uganda: a prospective cohort study. PLOS Med 2011; 8: e1000427. 
10 Kim YH, Suh GY, Chung MP, et al. Treatment of isoniazid-resistant pulmonary 
tuberculosis. BMC Infectious Diseases 2008; 8: 6. 
11 Lee H, Jeong BH, Park HY, et al. Treatment Outcomes with Fluoroquinolone-
Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis. Antimicrob 
Agents Chemother 2015; 60: 471-7. 
12 Munang ML, Kariuki M, Dedicoat M. Isoniazid-resistant tuberculosis in 
Birmingham, United Kingdom, 1999-2010. QJM 2015; 108: 19-25. 
13 The Netherlands National TB Surveillance. Unpublished data. 
14 New York Department of Health and Mental Hygiene. New York City TB 
Surveillance - Unpublished data. 
15 Ohkado A, Aguiman L, Adlawan S, et al. Tuberculosis drug resistance and 
treatment outcomes under DOTS settings in large cities in the Philippines. The 
International Journal of Tuberculosis and Lung Disease 2006; 10: 283-9. 
IPD of INHR-TB - Supplemental Tables 
Manuscript accepted for publication at the Lancet Respiratory Medicine 26 
16 Park JS, Lee JY, Lee YJ, et al. Serum Levels of Antituberculosis Drugs and Their 
Effect on Tuberculosis Treatment Outcome. Antimicrob Agents Chemother 2015; 
60: 92-8. 
17 Quy H, Cobelens F, Lan N, Buu T, Lambregts C, Borgdorff M. Treatment 
outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi 
Minh City, Vietnam. The International Journal of Tuberculosis and Lung Disease 
2006; 10: 45-51. 
18 Quy H, Lan N, Borgdorff M, et al. Drug resistance among failure and relapse cases 
of tuberculosis: is the standard re-treatment regimen adequate? The International 
Journal of Tuberculosis and Lung Disease 2003; 7: 631-6. 
19 Reves R, Heilig C, Tapy J, et al. Intermittent tuberculosis treatment for patients 
with isoniazid intolerance or drug resistance. The International Journal of 
Tuberculosis and Lung Disease 2014; 18: 571-80. 
20 Romanowski K, Chiang LY, Roth DZ, et al. Treatment outcomes for isoniazid-
resistant tuberculosis under program conditions in British Columbia, Canada. BMC 
Infect Dis 2017; 17: 604. 
21 Skrahina A. Unpublished data (Belarus). 
22 Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-
month intermittent treatment regimen in HIV-infected patients with tuberculosis: a 
randomized clinical trial. Am J Respir Crit Care Med 2010; 181: 743-51. 
23 Viiklepp P. Unpublished data (Estonia). 
24 Yoshiyama T, Shrestha B, Maharjan B. Risk of relapse and failure after retreatment 
with the Category II regimen in Nepal. The International Journal of Tuberculosis 
and Lung Disease 2010; 14: 1418-23. 
25 Banu Rekha VV, Rajaram K, Kripasankar AS, et al. Efficacy of the 6-month thrice-
weekly regimen in the treatment of new sputum smear-positive pulmonary 
tuberculosis under clinical trial conditions. Natl Med J India 2012; 25: 196-200. 
26 Bonnet MP, Manuela; Meacci, Francesca; Orrù, Germano; Yesilkaya, Hasan; 
Jarosz, Thierry; Andrew, Peter W; Barer, Mike; Checchi, Francesco; Rinder, Heinz. 
Treatment of tuberculosis in a region with high drug resistance: outcomes, drug 
resistance amplification and re-infection. Plos ONE 2011; 6: e23081-e. 
27 Cegielski P, Griffith D (Personal communication). Unpublished data (Texas, USA).  
28 Escalante PG, Edward A; Griffith, David E; Musser, James M; Awe, Robert J. 
Treatment of isoniazid-resistant tuberculosis in southeastern Texas. CHEST Journal 
2001; 119: 1730-6. 
29 Garcia-Prats AJ, du Plessis L, Draper HR, et al. Outcome of culture-confirmed 
isoniazid-resistant rifampicin-susceptible tuberculosis in children. Int J Tuberc 
Lung Dis 2016; 20: 1469-76. 
30 Gillespie SH, Crook A, McHugh T, et al. Four-Month Moxifloxacin-Based 
Regimens for Drug-Sensitive Tuberculosis. N Eng J Med 2014; 371: 1577-87. 
31 Guerra-Assuncao JA, Houben RM, Crampin AC, et al. Recurrence due to relapse or 
reinfection with Mycobacterium tuberculosis: a whole-genome sequencing 
approach in a large, population-based cohort with a high HIV infection prevalence 
and active follow-up. J Infect Dis 2015; 211: 1154-63. 
32 Merle C, Fielding K, Sow OB, et al. A Four-Month Gatifloxacin-Containing 
Regimen for Treating Tuberculosis. N Engl J Med 2014; 371: 1588-98. 
IPD of INHR-TB - Supplemental Tables 
Manuscript accepted for publication at the Lancet Respiratory Medicine 27 
33 Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of 
once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated 
tuberculosis: a randomized clinical trial. Clin Infect Dis 2011; 53: 716-24. 
34 Tabarsi P, Baghaei P, Hemmati N, et al. Comparison of the effectiveness of 2 
treatment regimens in patients with isoniazid-resistant tuberculosis. 2009. 
 
